ROSSI DINO A sold $8.2M of KRYS
ROSSI DINO A sold 25,000 shares of Krystal Biotech, Inc. (KRYS) at an average of $329.12 ($325.60–$333.23, $8.23M total) across 8 trades on 2026-08-14.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete insider behavior datapoint (open-market sale totaling about $8.23M) but does not include new operational, financial, or regulatory information about KRYS.
Market read
Traders may briefly reassess sentiment around KRYS due to director selling, but the event is unlikely to drive a sustained repricing without additional fundamental news.
What to watch
No 10b5-1 plan is stated, but the filing alone does not confirm intent; traders should watch for subsequent insider buys, additional Form 4s, or any company-specific catalysts.
Background
This is an SEC Form 4 insider transaction for Krystal Biotech, Inc., reported by a director.
Ticker impact
Krystal Biotech director Rossi Dino A sold $8.23M of KRYS shares in an open-market Form 4 on 2026-08-14.
Limited immediate impact; any effect is likely short-lived unless followed by additional disclosures or company-specific news.
The filing is a routine Form 4 open-market sale with no 10b5-1 plan and a large notional value, but it does not disclose new company fundamentals or guidance.
Market effects
No clear sector read-through from a single director sale without accompanying company or pipeline news.
None.
None.
Counterpoint
The sale could be for diversification, taxes, or pre-planned liquidity needs, especially given multiple same-day trades across a narrow price band.
Key entities
- issuerKrystal Biotech, Inc.
Subject of the Form 4 insider sale disclosure (KRYS).
- insiderRossi Dino A
Director who sold 25,000 shares across eight trades on 2026-08-14.
